Remus Pharmaceuticals
REMUS NSE
Remus Pharmaceuticals
HealthcareNSE: REMUS Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹1,025 Cr
Volatility
Moderate
P/E Ratio
22.8
EBITDA
₹56.69 Cr
Return on Equity
13.6%
Debt to Equity
0.08
Book Value
₹297.86
EPS
₹36.55
52W High
₹987.5
52W Low
₹580
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Debtor days have improved from 107 to 59.8 days.
Weaknesses
1- Company has a low return on equity of 13.0% over last 3 years.
Growth Rate
Revenue Growth
36.52% lower than
3Y
Net Income Growth
19.48% lower than
3Y
Cash Flow Change
94.17% higher than
3Y
ROE
-45.38% lower than
3Y
ROCE
-47.67% level than
3Y
EBITDA Margin (Avg.)
-18.64% higher than
3Y
Quarterly Results
| Particulars | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 29 | 185 | 273 | 348 | 400 | 453 |
| Expenses | 20 | 165 | 252 | 323 | 373 | 424 |
| Operating Profit | 9 | 20 | 20 | 25 | 27 | 30 |
| OPM % | 32% | 11% | 8% | 7% | 7% | 7% |
| Other Income | 2 | 3 | 3 | 3 | 3 | 4 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 |
| PBT | 10 | 22 | 22 | 25 | 28 | 31 |
| Tax % | 25% | 15% | 16% | 19% | 23% | 21% |
| Net Profit | 6 | 19 | 19 | 21 | 22 | 25 |
| EPS in Rs | 4.87 | 13.16 | 11.87 | 13.57 | 14.85 | 16.54 |
Profit & Loss
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 213 | 620 | 854 |
| Expenses | 184 | 575 | 797 |
| Operating Profit | 29 | 46 | 57 |
| OPM % | 14% | 7% | 7% |
| Other Income | 3 | 5 | 7 |
| Interest | 0 | 1 | 1 |
| Depreciation | 1 | 2 | 3 |
| PBT | 30 | 47 | 59 |
| Tax % | 20% | 19% | 22% |
| Net Profit | 24 | 38 | 46 |
| EPS in Rs | 17.69 | 24.64 | 31.39 |
| Div. Payout % | 4% | 3% | 2% |
Balance Sheet
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 1 | 6 | 12 |
| Reserves | 156 | 250 | 339 |
| Borrowings | 14 | 23 | 27 |
| Other Liabilities | 161 | 154 | 201 |
| Total Liabilities | 333 | 433 | 579 |
| Fixed Assets | 14 | 16 | 18 |
| CWIP | 0 | 0 | 8 |
| Investments | 105 | 186 | 275 |
| Other Assets | 215 | 231 | 277 |
| Total Assets | 333 | 433 | 579 |
Cash Flow
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | 4 | 7 | 18 |
| Investing | -9 | -11 | -15 |
| Financing | 24 | 6 | 1 |
| Net Cash Flow | 19 | 3 | 5 |
| Free Cash Flow | 3 | 3 | 4 |
| CFO/OP | 35 | 32 | 49 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 198 | 64 | 60 |
| Inventory Days | 96 | 35 | 35 |
| Days Payable | 209 | 49 | 37 |
| Cash Conversion Cycle | 85 | 50 | 58 |
| Working Capital Days | 98 | 54 | 57 |
| ROCE % | — | 20% | 17% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Remus Pharmaceuticals insights
63 extracted metrics + investor summaries across FY20–FY26.
Documents
1
Copy of Newspaper Publication
8 Sep - Published newspaper notice for 11th AGM, FY26 annual report dispatch, and e-voting details on September 8, 2026. 8 Sep - Published newspaper notice for 11th AGM, FY26 annual report dispatch, and e-voting details on September 8, 2026.
2
Record Date
7 Sep - Record date fixed for final dividend of Rs. 0.50 per share; AGM on September 29, 2026. 7 Sep - Record date fixed for final dividend of Rs. 0.50 per share; AGM on September 29, 2026.
3
Shareholders meeting
7 Sep - Remus Pharmaceuticals' 11th AGM is on September 29, 2026; e-voting runs September 25-28. 7 Sep - Remus Pharmaceuticals' 11th AGM is on September 29, 2026; e-voting runs September 25-28.
4
Copy of Newspaper Publication
6 Sep - Newspaper clippings submitted for postal ballot notice dispatch completion and e-voting information on September 6, 2026. 6 Sep - Newspaper clippings submitted for postal ballot notice dispatch completion and e-voting information on September 6, 2026.
5
Shareholders meeting
5 Sep - Postal ballot seeks approval to migrate shares from NSE Emerge to NSE and BSE main boards. 5 Sep - Postal ballot seeks approval to migrate shares from NSE Emerge to NSE and BSE main boards.
Frequently Asked Questions about Remus Pharmaceuticals
What does Remus Pharmaceuticals Ltd do?
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
Where is Remus Pharmaceuticals Ltd (REMUS) listed?
Remus Pharmaceuticals Ltd trades as REMUS on the NSE.
Which sector does Remus Pharmaceuticals Ltd belong to?
Remus Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd has a market capitalisation of ₹1,025 Cr, which places it in the Small Cap band.
What is the PE ratio of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd trades at a PE ratio of 22.80, on earnings per share of ₹36.55, against a book value of ₹297.86 per share.
What is the 52-week high and low of Remus Pharmaceuticals Ltd?
Over the last 52 weeks Remus Pharmaceuticals Ltd has traded between ₹580 and ₹987.5.
Does Remus Pharmaceuticals Ltd pay dividends?
Remus Pharmaceuticals Ltd has a dividend yield of 0.06%.
What is the Return on Equity (ROE) of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd reported a return on equity of 13.60%. Its debt-to-equity ratio is 0.08.
Company Information
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/REMUS.md for Remus Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.